🏅 FDA Orphan Designation

Hizentra

Immune Globulin Subcutaneous (Human), 20% Liquid

Manufacturer: CSL Behring

Indicated for:

Chronic inflammatory demyelinating polyneuropathyOrphan

FDA-Approved Indications (1)

Chronic inflammatory demyelinating polyneuropathyOrphan Designation

Indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.

Indications & Usage

Indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.